Alexza Pharmaceuticals, Inc. announced a private placement equity offering of 8.1 million shares of common stock to several qualified institutional investors. The company will receive $2.4325 per share, or approximately $19.1 million in net proceeds.

Alexza Pharmaceuticals also issued 7.3 million warrants as part of the deal. The warrants entitle the holder to purchase 0.9 shares of common stock at $2.77 per share. The warrants expire in seven years.

Alexza Pharmaceuticals is developing a proprietary drug delivery technology called the Staccato® system. This technology vaporizes unformulated pharmaceutical drugs into an aerosol form that allows rapid systemic delivery through lung inhalation.

Alexza Pharmaceuticals has completed Phase 3 trials for using this technology to deliver Loxapine for use in treating schizophrenic or bipolar disorder patients. The company plans a new drug application submission in 2010.

Staccato® is also being tested for use in other areas, including the treatment of migraine headaches, pain and insomnia.

Let us hear your thoughts below:

Last 5 posts by QualityStocks

• Novavax, Inc. (NVAX) Prices Offering Of Common Stock - November 24th, 2009
• Freshwater Technologies (FWTC.OB) Water Activation Technology Increases the Germination of Vegetable Crops - November 24th, 2009
• AlumniFuel Power Corp. (AFPW.OB) Subsidiary Turns Heads with Technology at Naval Energy Forum - November 24th, 2009
• Provectus Pharmaceuticals Inc. (PVCT.OB) Delivers Favorable Oncology Treatment; Presents Data to 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers - November 24th, 2009
• TapImmune, Inc. (TPIV.OB) Among the Winners in the Booming Vaccine Business - November 24th, 2009